# EDGAR Filing Document

**Accession Number:** 0001676725
**File Stem:** 0001193125-26-054973
**Filing Date:** 2026-2
**Character Count:** 22773
**Document Hash:** c610fb7e12dd79b25ecb627b34e8d492
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-054973.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001193125-26-054973

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**EFFECTIVENESS DATE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IDEAYA Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001676725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474268251
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293525
- **FILM NUMBER:** 26643096

**BUSINESS ADDRESS:**
- **STREET 1:** 5000 SHORELINE CT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-443-6209

**MAIL ADDRESS:**
- **STREET 1:** 5000 SHORELINE CT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ideaya Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20160609

**As filed with the Securities and Exchange Commission on February 17, 2026** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**IDEAYA Biosciences, Inc.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **47-4268251** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

---

| | |
|:---|:---|
| **5000 Shoreline Court, Suite 300**<br>**South San Francisco, California** | **94080** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2019 Incentive Award Plan** 

**2019 Employee Stock Purchase Plan** 

 **(Full Title of the Plan)** 

------

**Yujiro Hata** 

**President and Chief Executive Officer** 

**IDEAYA Biosciences, Inc.** 

**5000 Shoreline Court, Suite 300** 

**South San Francisco, California 94080** 

**(650) 443-6209** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copies to:*** 

**Mark V. Roeder, Esq.** 

**John C. Williams, Esq.** 

**Latham & Watkins LLP** 

**140 Scott Drive** 

**Menlo Park, California 94025** 

**Telephone: (650) 328-4600** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the "Commission") for the purpose of registering an additional 4,389,827 shares of common stock, par value $0.0001 per share ("common stock"), of IDEAYA Biosciences, Inc. (the "Registrant") issuable under the following employee benefit plans for which registration statements of the Registrant on Form S-8 (File Nos. [<u>333-231784</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158497/d732234ds8.htm), [<u>333-237362</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459020012528/idya-s8.htm), [<u>333-254617</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459021014848/idya-s8.htm), [<u>333-263657</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459022010903/idya-s8.htm), [<u>333-270334</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859ds8.htm), [<u>333-277189</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017024017149/idya_s-8_20240220.htm), [<u>333-285028</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022361/idya-20250218.htm)) are effective: (i) the IDEAYA Biosciences, Inc. 2019 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,511,862 shares of common stock and (ii) the IDEAYA Biosciences, Inc. Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 877,965 shares of common stock.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC").

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

*In this registration statement, IDEAYA Biosciences, Inc. is sometimes referred to as "Registrant," "we," "us" or "our."* 

**INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8**

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the SEC on May 28, 2019 (File No. [<u>333-231784</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158497/d732234ds8.htm)), March 24, 2020 (File No. [<u>333-237362</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459020012528/idya-s8.htm)), March 23, 2021 (File No. [<u>333-254617</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459021014848/idya-s8.htm)), March 17, 2022 (File No. [<u>333-263657</u>](https://www.sec.gov/Archives/edgar/data/1676725/000156459022010903/idya-s8.htm)), March 7, 2023 (File No. [<u>333-270334</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859ds8.htm)), February 20, 2024 (File No. [<u>333-277189</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017024017149/idya_s-8_20240220.htm)), and February 18, 2025 (File No. [<u>333-285028</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022361/idya-20250218.htm)) are incorporated by reference herein; except for Item 8, which is being updated by this Registration Statement.

**Item 3. Incorporation of Documents by Reference.** 

The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following documents previously filed with the SEC:

(a) Our Annual Report on [<u>Form 10-K</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm) for the year ended December 31, 2025 filed with the SEC on February 17, 2026;

(b) Our Current Reports on Form 8-K filed with the SEC on [<u>January 12, 2026</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/d93674d8k.htm) and [<u>February 17, 2026</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312526052741/idya-20260217.htm) ;

(c) The information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K from our Definitive Proxy Statement on [<u>Schedule 14A</u>](https://www.sec.gov/Archives/edgar/data/1676725/000095017025060530/idya-20250430.htm) , filed with the SEC on April 30, 2025; and

------

(d) The description of the Registrant's common stock contained in the Registrant's "Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934" filed as [<u>Exhibit 4.3</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-ex4_3.htm) to our Annual Report on Form 10-K for the year ended December 31, 2025 and any amendments or reports filed for the purpose of updating such description.

All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

**Item 8. Exhibits.**

**Exhibit Index** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | **Exhibit Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed**<br>**Herewith** |
| **Exhibit**<br>**Number** | **Exhibit Description** | **Form** | **Date** | **Number** | **Filed**<br>**Herewith** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex31.htm) | 8-K | 5-28-19 | 3.1 |  |
| 4.2 | [<u>Amended and Restated Bylaws.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex32.htm) | 8-K | 5-28-19 | 3.2 |  |
| 4.3 | [<u>Form of Common Stock Certificate.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex42.htm) | S-1/A | 5-13-19 | 4.2 |  |
| 5.1 | [<u>Opinion of Latham & Watkins LLP.</u>](idya-ex5_1.htm) |  |  |  | X |
| 23.1 | [<u>Consent of Independent Registered Public Accounting Firm.</u>](idya-ex23_1.htm) |  |  |  | X |
| 23.2 | [<u>Consent of Latham & Watkins LLP (included in Exhibit 5.1).</u>](idya-ex5_1.htm) |  |  |  | X |
| 24.1 | [<u>Power of Attorney. Reference is made to the signature page to the Registration Statement.</u>](#powerofattorney) |  |  |  | X |
| 99.1(a)# | [<u>2019 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158497/d732234dex992a.htm) | S-8 | 5-28-19 | 99.2<br> (a) |  |
| 99.1(b)# | [<u>Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105b.htm) | S-1 | 5-13-19 | 10.5<br> (b)  |  |
| 99.1(c)# | [<u>Form of Restricted Stock Award Agreement under the 2019 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105c.htm) | S-1 | 5-13-19 | 10.5<br> (c)  |  |
| 99.1(d)# | [<u>Form of Restricted Stock Unit Award Grant Notice under the 2019 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105d.htm) | S-1 | 5-13-19 | 10.5<br> (d)  |  |
| 99.2# | [<u>2019 Employee Stock Purchase Plan.</u>](https://www.sec.gov/Archives/edgar/data/1676725/000119312519158497/d732234dex993.htm) | S-8 | 5-28-19 | 99.3 |  |
| 107 | [<u>Filing Fee Table</u>](idya_exfilingfees.htm). |  |  |  | X |

---

# Indicates management contract or compensatory plan.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 17th day of February, 2026.

---

| | |
|:---|:---|
| **IDEAYA Biosciences, Inc.** | **IDEAYA Biosciences, Inc.** |
| By: | /s/ Yujiro Hata |
|  | Yujiro Hata |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Yujiro Hata and Joshua Bleharski, Ph.D., and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yujiro Hata<br>Yujiro Hata | President, Chief Executive Officer and Director<br>*(Principal Executive Officer)* | February 17, 2026<br>|
| /s/ Joshua Bleharski, Ph.D.<br>Joshua Bleharski, Ph.D. | Chief Financial Officer<br>*(Principal Financial Officer)* | February 17, 2026<br>|
| /s/ Andres Ruiz Briseno | Chief Accounting Officer<br>*(Principal Accounting Officer)* | February 17, 2026 |
| Andres Ruiz Briseno | Chief Accounting Officer<br>*(Principal Accounting Officer)* | February 17, 2026 |
| /s/ Terry Rosen, Ph.D.<br>Terry Rosen, Ph.D. | Chairman of the Board of Directors | February 17, 2026<br>|
| /s/ Garret Hampton, Ph.D.<br>Garret Hampton, Ph.D. | Director | February 17, 2026<br>|
| /s/ Catherine Mackey, Ph.D.<br>Catherine Mackey, Ph.D. | Director | February 17, 2026<br>|
| /s/ Scott Morrison<br>Scott Morrison | Director | February 17, 2026<br>|
| /s/ Jeffrey Stein, Ph.D. | Director | February 17, 2026 |
| Jeffrey Stein, Ph.D. | Director | February 17, 2026 |
| /s/ Wendy Yarno<br>Wendy Yarno | Director | February 17, 2026<br>|

---

------

## Exhibit 5.1

![img113933597_0.jpg](img113933597_0.jpg) **Exhibit 5.1**

IDEAYA Biosciences, Inc.

5000 Shoreline Court, Suite 300

South San Francisco, CA 94080

Re: Registration Statement on Form S-8; 4,389,827 shares of Common Stock of IDEAYA Biosciences, Inc., par value $0.0001 per share

To the addressee set forth above:

We have acted as special counsel to IDEAYA Biosciences, Inc., a Delaware corporation (the "***Company***"), in connection with the registration by the Company of an aggregate 4,389,827 shares of common stock of the Company, par value $0.0001 per share (the "***Shares***"), issuable under the Company's 2019 Incentive Award Plan (the "***2019 Plan***") and 2019 Employee Stock Purchase Plan (the "***ESPP***" and together with the 2019 Plan, the "***Plans***").

The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the "***Act***"), filed with the Securities and Exchange Commission (the "***Commission***") on February 17, 2026 (the "***Registration Statement***"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the "***DGCL***"), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the Plans, assuming in each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the applicable Plans (and the agreements and awards duly adopted

------

**February 17, 2026**<br>**Page 2**<br>

![img113933597_1.jpg](img113933597_1.jpg)

thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

/s/ Latham & Watkins LLP

------

## Exhibit 23.1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Exhibit 23.1** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of IDEAYA Biosciences, Inc. of our report dated February 17, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in IDEAYA Biosciences, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

San Jose, California

February 17, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form** S-8

(Form Type)

IDEAYA Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered** | **Proposed Maximum Offering Price Per Share**  | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Fees to be Paid | 1 | Equity | 2019 Incentive Award Plan<br>Common Stock, par value $0.0001 per share<br>| 457(c)<br>and 457(h)<br>| 3511862 | $32.765 | $115066158.43 | $0.0001381 | $15890.64 |
| Fees to be Paid | 1 | Equity | 2019 Employee Stock Purchase Plan<br>Common Stock, par value $0.0001 per share<br>| 457(c)<br>and 457(h)<br>| 877965 | $32.765 | $28766523.23 | $0.0001381 | $3972.66 |
|  |  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | $143832681.66 |  | $19863.30 |
|  |  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  | - |
|  | 2 | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  | - |
|  |  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  | $19863.30 |

---

(1)Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock, par value $0.0001 per share ("Common Stock"), of IDEAYA Biosciences, Inc. (the "Registrant") that become issuable under the Registrant's 2019 Incentive Award Plan or the Registrant's Employee Stock Purchase Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.

Estimated solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, the proposed maximum offering price per share and proposed maximum aggregate offering price are based upon the average of the high and low prices of the Registrant's shares of Common Stock as reported on the Nasdaq Global Select Market on February 10, 2026, which date is within five business days prior to the filing of this Registration Statement.

(2)The Registrant does not have any fee offsets.

------